InsiderTrades

Form 4 for IBRX ImmunityBio, Inc.

Accepted 2024-12-16 00:00:00 ET · period of report 2024-12-15 · accession 0001326110-24-000118 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-12-16 2024-12-15 IBRX LAUER REGAN J CAO M - OptEx $0.00 +21.0K 115.4K +22% $0
D 2024-12-16 2024-12-15 IBRX LAUER REGAN J CAO F - Tax $2.87 -7,503 107.9K -7% -$21.5K
D 2024-12-16 2024-12-15 IBRX LAUER REGAN J CAO M - OptEx $0.00 -21.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-12-15 M A 21,031 $0.00 115,365 D — —
2 Common Common Stock 2024-12-15 F D 7,503 $2.87 107,862 D — — (F1) On December 15, 2024, the Reporting Person's restricted stock units ("RSUs") vested. The closing price of Immunity Bio, Inc.'s common stock on December 13, 2024 was the settlement price used to calculate the shares withheld.
3 Derivative Restricted Stock Units 2024-12-15 M D 21,031 $0.00 0 D — · — to — 21,031 Common Stock (F2) Each RSU represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F3) Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the RSUs vested as follows: 1/3rd of the RSUs subject to the award vested June 15, 2023, 1/3rd of the RSUs subject to the award vested December 15, 2023, and 1/3rd of the RSUs subject to the award vested December 15, 2024 such that the award was fully vested on December 15, 2024.